Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,910 | -10,309 | -5,491 | -3,599 | -1,104 |
| Depreciation Amortization | 9 | 15 | 21 | 16 | 34 |
| Accounts receivable | -104 | 240 | 123 | 239 | 225 |
| Accounts payable and accrued liabilities | -766 | 672 | 299 | 248 | -366 |
| Other Working Capital | -870 | 912 | 422 | 487 | -141 |
| Other Operating Activity | 1,105 | 2,155 | 256 | 174 | 185 |
| Operating Cash Flow | $-2,536 | $-6,315 | $-4,370 | $-2,435 | $-1,167 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 152 | -3,375 | -3,114 | -4,800 | -231 |
| Purchase Of Investment | N/A | N/A | -1,689 | N/A | N/A |
| Investing Cash Flow | $152 | $-3,375 | $-4,803 | $-4,800 | $-231 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 9,026 | 7,838 | 7,549 | 1,514 |
| Financing Cash Flow | $N/A | $9,026 | $7,838 | $7,549 | $1,514 |
| Beginning Cash Position | 4,109 | 4,773 | 4,773 | 4,773 | 4,773 |
| End Cash Position | 1,725 | 4,109 | 3,438 | 5,087 | 4,889 |
| Net Cash Flow | $-2,384 | $-664 | $-1,335 | $314 | $116 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,536 | -6,315 | -4,370 | -2,435 | -1,167 |
| Free Cash Flow | -2,536 | -6,315 | -4,370 | -2,435 | -1,167 |